Combination Therapy Shows Potential in Psoriasis, Obesity
Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.
By
Kathryn Wighton
May 20, 2026
Clinical Scorecard: Combination Therapy Shows Potential in Psoriasis, Obesity
At a Glance
Category Detail
Condition Moderate to severe plaque psoriasis with overweight or obesity Key Mechanisms Ixekizumab (IL-17 inhibitor) combined with tirzepatide (GLP-1 receptor agonist) Target Population Adult patients with moderate to severe plaque psoriasis and overweight or obesity Care Setting Outpatient, multi-site clinical trial
Key Highlights
27% of participants on combination therapy achieved complete skin clearance and weight reduction vs 6% on ixekizumab alone Significant improvements in PASI scores and weight reduction with combination therapy 84% of participants completed treatment through week 36 Gastrointestinal events more common in combination therapy group No new safety concerns reported Guideline-Based Recommendations
Diagnosis
Evaluate for moderate to severe plaque psoriasis with PASI of 12 or greater Assess for overweight or obesity with at least one weight-related comorbidity Management
Consider ixekizumab plus tirzepatide for patients not responding to monotherapy Individualized diet and exercise counseling recommended Monitoring & Follow-up
Monitor for treatment-emergent adverse events, particularly gastrointestinal symptoms Assess cardiometabolic measures regularly Risks
Increased incidence of gastrointestinal events with combination therapy Serious adverse events occurred in 4% of combination therapy group Patient & Prescribing Data
Adults with moderate to severe plaque psoriasis and overweight or obesity
Combination therapy shows superior efficacy in achieving weight loss and skin clearance
Clinical Best Practices
Utilize combination therapy for enhanced treatment outcomes in eligible patients Ensure regular follow-up to monitor efficacy and adverse effects Educate patients on potential gastrointestinal side effects Related Resources & Content
